Subscribe to RSS
DOI: 10.1055/s-2007-982577
A Concise Stereoselective Total Synthesis of (2R,2′R)-threo-(+)-Methylphenidate via a Ring-Closing Metathesis Protocol [1]
Publication History
Publication Date:
25 June 2007 (online)
Abstract
In the synthesis of (2R,2′R)-threo-(+)-methylphenidate, a ring-closing metathesis approach was adopted to construct the piperidine ring, while Sharpless asymmetric epoxidation was used for the efficient generation of two contiguous stereocenters.
Key words
(2R,2′R)-threo-(+)-methylphenidate - ritalin - attention deficit hyperactivity disorder (ADHD) - cis-allylic alcohol - Sharpless asymmetric epoxidation - bisolefin - ring-closing metathesis (RCM)
IICT communication number 070106.
- 2
Volkow N.Ding Y.Fowler J.Wang O.Logan J.Gatley J.Dewey S.Ashby C.Libermann J.Hitzemann R.Wolf A. Arch. Gen. Psychiatry 1995, 52: 456 - 3
Schurri M.Skolnick P.Rafferty M.Rice K.Janowsky A.Paul SJ. Neurochem. 1985, 45: 1062 -
4a
Prashad M.Har D.Repic O.Blacklock TJ.Giannousis P. Tetrahedron: Asymmetry 1998, 9: 2133 -
4b
Faulconbridge S.Zavareh HS.Evans GR.Langston M. PCT Int. Appl. WO 98/25902, 1998; Chem. Abstr. 1998, 129, 67705 -
4c
Langston M.Zavareh HS. PCT Int. Appl. WO 97/28124, 1997; Chem. Abstr. 1997, 127, 205477 -
4d
Zavareh HS. PCT Int. Appl. WO 97/32851, 1997; Chem. Abstr. 1997, 127, 278144 -
5a
Axten JM.Ivy R.Krim L.Winkler DJ. J. Am. Chem. Soc. 1999, 121: 6511 -
5b
Prashad M. Adv. Synth. Catal. 2001, 343: 379 -
6a
Thai DL.Sapko MT.Reiter CT.Bierer DE.Perel JM. J. Med. Chem. 1998, 41: 591 -
6b
Prashad M.Kim H.-Y.Lu Y.Liu Y.Har D.Repic O.Blacklock TJ.Giannousis P. J. Org. Chem. 1999, 64: 1750 -
6c
Matsumura Y.Kanda Y.Shirai K.Onomura O.Maki T. Org. Lett. 1999, 1: 175 - 7
Radha Krishna P.Lopinti K.Kannan V. Tetrahedron Lett. 2004, 45: 7847 - 8
Radha Krishna P.Lopinti K. Synlett 2007, 83 - 9
Jeffery T.Gueugnot S.Linstrumelle G. Tetrahedron Lett. 1992, 33: 5757 - 10
Sandrine D.Jean-Luc P.Maurice S. Synthesis 1998, 1015 - 11
Katsuki T.Sharpless KB. J. Am. Chem. Soc. 1980, 102: 5974 -
12a
Katsuki T.Martin VS. Asymmetric Epoxidation of Allylic Alcohols, In Organic Reactions Vol. 48:Paquette LA. John Wiley & Sons; New York: 1996. p.1-299 -
12b
Ma S.Ni B. Chem. Eur. J. 2004, 10: 3286 - For examples of cuprate-mediated epoxide opening, see:
-
13a
Horita K.Tanaka K.Yonemitsu O. Chem. Pharm. Bull. 1993, 41: 2044 -
13b
Nicolaou KC.Murphy F.Barluenga S.Ohshima T.Wei H.Xu J.Gray DLF.Baudoin O. J. Am. Chem. Soc. 2000, 122: 3830 -
13c
Radha Krishna P.Ramana Reddy VV.Sharma GVM. Synthesis 2004, 2107 - 14
Staudinger H.Meyer J. Helv. Chim. Acta 1919, 2: 635 -
15a
Rutjes FPJT.Schoemaker HE. Tetrahedron Lett. 1997, 38: 677 -
15b
Huwe CM.Kiehl CO.Blechert S. Synlett 1996, 65 -
15c
Deiters A.Martin SF. Chem. Rev. 2004, 104: 2201 - 16
Martín R.Murruzzu C.Perricàs MA.Riera A. J. Org. Chem. 2005, 70: 2325 - 17
Dess DB.Martin JC. J. Am. Chem. Soc. 1991, 113: 7277
References and Notes
IICT communication number 070106.
18Spectral Data of Selected Compounds: Compound 7a: white solid; mp 49-52 °C; [α]D -10.30 (c = 0.55, CHCl3). 1H NMR (200 MHz, CDCl3): δ = 7.23-7.35 (m, 5 H, ArH), 5.69-5.89 (m, 1 H, olefin), 5.03-5.12 (m, 2 H, olefin), 3.88-4.12 (m, 3 H, OCH, OCH2), 2.88 (td, J = 4.50, 6.73 Hz, 1 H, CHPh), 2.15-2.27 (m, 1 H, allylic), 1.95-2.09 (m, 1 H, allylic). 13C NMR (75 MHz, CDCl3): δ = 138.44, 134.72, 129.37, 128.57, 127.19, 118.13, 71.52, 64.53, 52.55, 39.49. IR (KBr): 3386, 3077, 3028, 2929, 1453, 1037, 915, 703 cm-1. LC-MS: m/z (%) = 215 (17) [M + 23]. Anal. Calcd for C12H16O2: C, 74.97; H, 8.39. Found: C, 74.95; H, 8.40. Compound 10: [α]D -26.70 (c = 0.75, CHCl3). 1H NMR (200 MHz, CDCl3): δ = 7.60-7.70 (m, 5 H, ArH), 7.37-7.34 (m, 6 H, ArH), 7.14-7.25 (m, 4 H, ArH), 5.71-5.91 (m, 1 H, olefin), 5.04-5.15 (m, 2 H, olefin), 3.97-4.15 (m, 2 H, CHN3, CH), 3.74 (dd, J = 4.92, 9.85 Hz, 1 H, CH), 2.80-2.89 (m, 1 H, CH), 2.18 (t, J = 6.44 Hz, 2 H, allylic), 1.05 (br s, 9 H, t-Bu). IR (KBr): 3069, 2931, 2858, 2102, 1427, 1109, 701, 503 cm-1. LC-MS: m/z (%) = 456 (30) [M + 1]. Anal. Calcd for C28H33N3OSi: C, 73.80; H, 7.30. Found: C, 73.74; H, 7.28. Compound 11: [α]D +25.80 (c = 0.55, CH 2Cl2). 1H NMR (300 MHz, CDCl3): δ = 7.53-7.62 (m, 4 H, ArH), 7.30-7.41 (m, 6 H, ArH), 7.19-7.25 (m, 3 H, ArH), 7.12 (br s, 1 H, NH), 6.97-7.00 (m, 2 H, ArH), 6.41 (td, J = 4.53, 8.69 Hz, 1 H, olefin), 5.86 (d, J = 9.82 Hz, 1 H, olefin), 3.96-4.07 (m, 2 H, OCH, NCH), 3.85 (dd, J = 3.78, 10.58 Hz, 1 H, OCH), 2.84-2.91 (m, 1 H, CH), 1.93-2.00 (m, 2 H, allylic), 1.09 (br s, 9 H, t-Bu). 13C NMR (75 MHz, CDCl3): δ = 166.03, 140.24, 135.64, 135.56, 132.62, 129.97, 129.86, 128.79, 128.05, 127.88, 127.8, 127.34, 124.65, 67.67, 54.78, 51.88, 28.89, 26.9, 19.07. IR (KBr): 3370, 2924, 2854, 1675, 1611, 1109, 702 cm-1. LC-MS: m/z (%) = 456 (34) [M + 1]. Anal. Calcd for C29H33NO2Si: C, 76.44; H, 7.30. Found: C, 76.41; H, 7.28. Compound 13: [α]D +21.32 (c = 0.75, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 7.51-7.57 (m, 3 H, ArH), 7.29-7.38 (m, 6 H, ArH), 7.11-7.25 (m, 6 H, ArH), 3.98 (dd, J = 6.04, 10.20 Hz, 1 H, OCH2), 3.89 (dd, J = 5.67, 10.58 Hz, 1 H, OCH2), 2.89-3.06 (m, 2 H, CH2NH), 2.74-2.81 (m, 1 H, CHNH), 2.60 (td, J = 2.64, 11.71 Hz, 1 H, CHPh), 2.19-2.24 (m, 1 H, NH), 1.61 (dd, J = 12.84, 43.81 Hz, 2 H, CH2), 1.17-1.44 (m, 4 H, 2 × CH2), 1.01 (br s, 9 H, t-Bu). 13C NMR (75 MHz, CDCl3): δ = 139.30, 135.60, 135.30, 134.80, 129.60, 128.80, 128.20, 127.60, 127.13, 67.40, 62.30, 59.20, 50.90, 45.80, 30.16, 29.60, 26.80, 26.50, 25.60, 24.70, 24.50, 23.40, 22.70, 18.90. IR (KBr): 3356, 2930, 2855, 1427, 1109, 702 cm-1. LC-MS: m/z (%) = 444 (35) [M + 1]. Anal. Calcd for C29H37NOSi: C, 78.50; H, 8.41. Found: C, 78.49; H, 8.44. Compound 15: white solid; mp 78-80 °C; [α]D +12.70 (c = 0.50, CH2Cl2). 1H NMR (300 MHz, CDCl3): δ = 7.19-7.37 (m, 5 H, ArH), 4.60 (d, J = 12.08 Hz, 1 H), 4.00 (d, J = 12.84 Hz, 1 H), 3.66-3.70 (m, 1 H), 3.47-3.55 (m, 2 H), 3.01 (d, J = 12.08 Hz, 1 H), 2.84 (d, J = 10.8 Hz, 1 H), 1.62-1.66 (m, 2 H), 1.50 (br s, 9 H, t-Bu), 1.32-1.43 (m, 4 H). 13C NMR (50 MHz, CDCl3): δ = 156.40, 141.20, 128.80, 128.50, 126.70, 80.40, 63.50, 50.20, 45.80, 39.80, 28.40, 26.03, 25.36, 18.80. IR (KBr): 3448, 2928, 2840, 1681, 1598, 1258, 1158 cm-1. LC-MS: m/z (%): 328 (26) [M + Na]. Anal. Calcd for C18H27NO3: C, 70.79; H, 8.91. Found: C, 70.77; H, 8.93. Compound 16: white solid; mp 115-120 °C; [α]D = -40.66 (c = 0.80, CH2Cl2). 1H NMR (300 MHz, CDCl3): δ = 7.25-7.46 (m, 5 H, ArH), 4.73-5.03 (m, 1 H, NCH), 4.10 (d, J = 11.7 Hz, 1 H, CHPh), 3.88-4.00 (m, 1 H, NCH), 2.85-3.14 (m, 1 H, NCH), 1.72-1.88 (m, 6 H, 3 × CH2), 1.42 (br s, 9 H, t-Bu). 13C NMR (75 MHz, CDCl3): δ = 176.90, 154.8, 135.88, 128.80, 128.70, 127.80, 79.88, 54.02, 53.04, 51.17, 39.80, 38.30, 29.67, 28.23, 25.20, 18.80. IR (KBr): 3447, 2924, 2854, 1631, 1260, 760 cm-1. LC-MS: m/z (%) = 342 (22) [M + 23]. Anal. Calcd for C18H25NO4: C, 67.69; H, 7.89. Found: C, 67.66; H, 7.85.